UroGen Pharma (URGN) Retained Earnings (2016 - 2025)
Historic Retained Earnings for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$933.4 million.
- UroGen Pharma's Retained Earnings fell 2142.42% to -$933.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$933.4 million, marking a year-over-year decrease of 2142.42%. This contributed to the annual value of -$806.2 million for FY2024, which is 1867.58% down from last year.
- Latest data reveals that UroGen Pharma reported Retained Earnings of -$933.4 million as of Q3 2025, which was down 2142.42% from -$900.0 million recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Retained Earnings registered a high of -$382.4 million during Q1 2021, and its lowest value of -$933.4 million during Q3 2025.
- In the last 5 years, UroGen Pharma's Retained Earnings had a median value of -$631.5 million in 2023 and averaged -$638.3 million.
- Per our database at Business Quant, UroGen Pharma's Retained Earnings plummeted by 4387.57% in 2021 and then plummeted by 1717.67% in 2024.
- Quarter analysis of 5 years shows UroGen Pharma's Retained Earnings stood at -$467.3 million in 2021, then fell by 23.49% to -$577.1 million in 2022, then decreased by 17.72% to -$679.3 million in 2023, then dropped by 18.68% to -$806.2 million in 2024, then decreased by 15.77% to -$933.4 million in 2025.
- Its Retained Earnings was -$933.4 million in Q3 2025, compared to -$900.0 million in Q2 2025 and -$850.1 million in Q1 2025.